Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Basimglurant - Noema Pharma

Drug Profile

Basimglurant - Noema Pharma

Alternative Names: NOE-101; RG-7090; RO-4917523

Latest Information Update: 02 Jun 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Noema Pharma; Roche
  • Class Analgesics; Antidepressants; Antiepileptic drugs; Fluorobenzenes; Halogenated hydrocarbons; Imidazoles; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Trigeminal neuralgia
  • Phase II Tuberous sclerosis
  • Discontinued Fragile X syndrome; Major depressive disorder

Most Recent Events

  • 28 Feb 2022 Phase-II clinical trials in Tuberous sclerosis (Adjunctive treatment, In children, In adolescents) in USA (Parenteral) (NCT05059327)
  • 14 Feb 2022 The US FDA authorises an IND application for a phase IIb clinicial trial of basimglurant in Trigeminal neuralgia
  • 14 Feb 2022 Noema Pharma plans a phase IIb clinicial trial of basimglurant in Trigeminal neuralgia in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top